medcelerator · clinician one-pager

New Once-Daily Pill for Adults With HIV on Complex Treatment

Bixlenvo (bictegravir and lenacapavir) — a once-daily two-drug pill for adults with HIV who are already undetectable, including people on complex multi-tablet regimens

FDA Approved · United States · September 11, 2026

Condition: HIV

Who this is for

This is for adults living with HIV who are already undetectable on a stable regimen — including people taking several pills a day or complex multi-drug combinations — and who may be candidates for labelled US Bixlenvo as a once-daily switch. It explains the August 2026 FDA approval, the ARTISTRY Week 48 suppression numbers, the two-day Sunlenca start, Gilead Advancing Access, and how to talk with an HIV clinician — without treating this as a first-start drug, a failing-treatment rescue, a DIY import, or “approved” as funded. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221104

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/bixlenvo-bictegravir-lenacapavir